The Propel bioabsorbable implant family came to Medtronic through its acquisition of IntersectENT in 2022. OM1 and Medtronic partnered on their study to focus on healthcare resource use and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS). They aimed to prove the association of Propel devices with reduced HCRU and surgical revisions after sinus surgery.
Ultimately, the companies hope to use data collected in the study to communicate with payers and expand coverage for the implants.
Get the full story at our sister site, Drug Delivery Business News.